TRPM-2 antisense therapy
US7732422B2 · kind B2 · utility
119Cited by
11References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 19, 2007 |
| Grant date | Jun 8, 2010 |
| Priority date | — |
| Expiry date | Jul 4, 2028 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/346
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Antisense therapy which reduces the expression of TRPM-2 provides therapeutic benefits in the treatment of cancer. Seq ID No. 4 (cagcagcagagtcttcatcat) is an antisense oligonucleotide which inhibits expression of TRPM-2 by tumor cells, and which can be combined with a pharmaceutically acceptable carrier suitable for human administration.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.